GILD Gilead Sciences Inc.

65.74
+0.19  (+0%)
Previous Close 65.55
Open 65.61
Price To Book 3.72
Market Cap 84278680000
Shares 1,282,000,000
Volume 4,865,965
Short Ratio
Av. Daily Volume 8,093,265

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 trial did not meet primary endpoint - February 11, 2019.
Selonsertib (GS-4997) - STELLAR 4
Nonalcoholic steatohepatitis (NASH)
Phase 2 enrollment completed 1Q 2018.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Sjogren’s syndrome
Phase 2 data 2Q 2018.
GS-9674
Primary sclerosing cholangitis
Phase 2 data released November 9, 2018.
GS-9674
Primary biliary cholangitis
Phase 2 trial to complete enrolment 4Q 2019.
GS-5734
Ebola
Phase 3 data due 2Q 2019.
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 2 enrolment to be completed 2Q 2020.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-5)
Indolent B-Cell Non-Hodgkin Lymphoma
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 data due 1Q 2019.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 data released September 11, 2018. Endpoints met.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 2 data released September 6, 2018. Primary endpoint met.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2 data released May 30, 2018 - primary endpoint met.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 3 futility analysis 3Q 2017. Trial to continue.
Andecaliximab GS-5745
Gastric Cancer
Approved February 7, 2018.
Bictegravir/F/TAF
HIV
Phase 2 data 4Q 2018.
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 3 data due 2Q 2019.
Selonsertib (GS-4997) - STELLAR 3
Nonalcoholic steatohepatitis (NASH)
Phase 2 data released October 24, 2017. Positive high dose data, low dose negative.
GS-0976
Nonalcoholic steatohepatitis (NASH)
Approval announced July 18, 2017.
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
Hepatitis C virus (HCV)
Phase 2 ongoing.
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 initiated November 2016. Enrollment to be completed 2H 2019.
Filgotinib - DIVERSITY
Crohn’s disease
Phase 3 data due 1Q 2019.
Filgotinib - FINCH 1
Rheumatoid arthritis (RA)
Regulatory filing 2H 2019.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 pivotal trial enrolment to be completed 2Q 2019.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 2 trial initiated 4Q 2018.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
2-year data at ASH 2018 noted 39% of patients were in an ongoing response. OS not yet reached.
Yescarta (axicabtagene ciloleucel)
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer
Phase 2 enrollment to be completed 3Q 2018.
KTE-C19 (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 trial to be initiated 4Q 2018.
KTE-C19 (ZUMA-8)
Chronic lymphocytic leukemia (CLL)
Phase 2 48-week data due 4Q 2019.
Selonsertib + GS-9674 combo
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due 3Q 2019.
GS-9131
HIV
Phase 3 enrollment to be completed 2H 2019.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-7)
Refractory diffuse large B-cell lymphoma (DLBCL)

Latest News

  1. What Are the Key Growth Catalysts for Gilead Sciences in 2019?
  2. Comparing Dividends and Interest Expenses for GILD and ABBV
  3. The Top 5 Biotech Stocks Are Facing Growth Challenges — Are Any Immune?
  4. GILD or ABBV: Which Is Controlling Its Expenses Better?
  5. What Pharma Investors Need to Know About Pfizer's Latest Disaster
  6. GILD or ABBV: Which Is Expected to Report Faster EPS Growth?
  7. What Analysts Are Recommending for GILD and ABBV in February
  8. 2 Frustrating Flops, Plus Welcome to the Wrinkle Wars
  9. The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
  10. Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
  11. Intercept Reports Positive Top-Line Data for NASH, Shares Up
  12. After Gilead Failed, Intercept Stock Rises On NASH Treatment Study
  13. Intercept Comes in First With Liver Drug, But Race Isn’t Over
  14. Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial
  15. Gilead Receives Approval in Canada for YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy for Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy
  16. Better Buy: Celgene vs. Gilead Sciences
  17. U.S. Medicare plans to track CAR-T cancer therapy outcomes
  18. Gilead Sciences, Inc. -- Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc.
  19. Medicare would cover CAR-T therapies under new CMS proposal
  20. Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst